v3.26.3
Stock-Based Compensation (Tables)
9 Months Ended
Sep. 30, 2026
Stock-Based Compensation  
Schedule of stock option activity

​

​

​

​

​

​

​

​

​

​

​

​

​

Weighted

​

Weighted

​

​

​

​

Average

​

Average

​

​

​

​

Exercise

​

Remaining

​

​

​

​

Price

​

Contractual

​

  ​ ​ ​

Shares

  ​ ​ ​

Per Share

  ​ ​ ​

Term (In Years)

Options outstanding at December 31, 2025

 

9,134,278

​

$

26.49

​

7.1

Granted

 

2,799,370

​

$

34.21

​

—

Exercised

 

(66,830)

​

$

27.46

​

—

Canceled

 

(291,169)

​

$

41.05

​

—

Options outstanding at September 30, 2026

 

11,575,649

​

$

27.98

​

7.2

Options vested and expected to vest at September 30, 2026

 

11,364,937

​

$

27.93

​

7.2

Options exercisable at September 30, 2026

 

6,458,473

​

$

25.75

​

5.8

Shares available for grant under the Celldex Therapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, effective as of June 25, 2026) at September 30, 2026

 

3,516,635

​

​

​

​

​

Schedule of stock-based compensation expense

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30,

​

Nine Months Ended September 30,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

​

​

(In thousands)

​

(In thousands)

Research and development

​

$

5,626

​

$

4,743

​

$

14,861

​

$

14,210

General and administrative

​

 

5,348

​

 

4,058

​

 

13,044

​

 

13,098

Total stock-based compensation expense

​

$

10,974

​

$

8,801

​

$

27,905

​

$

27,308

​

Schedule of assumptions used for the fair value of employee stock options granted

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended September 30,

​

Nine Months Ended September 30,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Expected stock price volatility

 

62 – 63%

​

76%

​

62 – 76%

​

76 – 81%

Expected option term

 

6.0 Years

​

6.0 Years

​

6.0 Years

​

6.0 Years

Risk-free interest rate

 

4.3 – 4.9%

​

4.0 – 4.2%

​

3.8 – 4.9%

​

4.0 – 4.7%

Expected dividend yield

 

None

​

None

​

None

​

None

​